

(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 483 105 B2

(12)

NEW EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the opposition decision:
17.01.2001 Bulletin 2001/03

(51) Int Cl.7: **A61K 9/70, A61K 47/14**

(45) Mention of the grant of the patent:
28.06.1995 Bulletin 1995/26

(21) Application number: **92100183.0**

(22) Date of filing: **21.12.1987**

(54) **Solid drug-delivery devices employing fatty acid esters or fatty alcohol ethers of alkanediols as percutaneous absorption enhancers**

Feste Vorrichtungen zur transdermalen Wirkstoffabgabe, die Fettsäureester bzw. Fettalkoholether von Alkandiole als Absorptionsförderer verwenden

Dispositifs pour la délivrance transdermique de médicaments utilisant des esters d'acides gras ou des éthers d'alcohols gras des alcanediols pour améliorer l'absorption

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(72) Inventor: **Cleary, Gary W.**
San Mateo, CA 94401 (US)

(30) Priority: **22.12.1986 US 945356**
23.04.1987 US 41793
30.07.1987 US 79801

(74) Representative: **Hallybone, Huw George et al**
CARPMAELS AND RANSFORD
43 Bloomsbury Square
London WC1A 2RA (GB)

(43) Date of publication of application:
29.04.1992 Bulletin 1992/18

(56) References cited
EP-A- 0 013 949 EP-A- 0 043 738
EP-A- 0 171 742 US-A- 4 568 343
US-A- 4 588 580

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
87402945.7 / 0 272 987

- Int. J. Pharmaceut. 33 (1986) 225
- Acta Pharm Sued 20 (1983) 443

(73) Proprietor: **Ortho-McNeil Pharmaceutical, Inc.**
Raritan, NJ 08869-0606 (US)

EP 0 483 105 B2

DescriptionTechnical Field

5 [0001] This invention is in the field of transdermal drug-delivery. More particularly it relates to a transdermal drug-delivery device in the form of a solid state laminated composite that is adapted to be adhered to the skin and that includes a multiplicity of spaced resilient structural laminas that provide the device with mechanical properties that enable the device to stretch in concert with the area of skin to which it is adhered and which facilitate its handling prior to application. One embodiment of the invention is particularly adapted for administering estradiol transdermally. An-
 10 other is particularly adapted for administering fentanyl or fentanyl derivatives transdermally. The invention also relates to pharmaceutical compositions and transdermal drug delivery devices that include fatty acid esters/ethers of alkanediols as percutaneous absorption enhancers.

Background of the Invention

15 [0002] A variety of devices have been proposed or used for administering drugs transdermally. These devices are generally laminated composites that include a reservoir layer that contains the drug, a pressure-sensitive adhesive layer by which the device is attached to the skin, and a backing layer that forms the outer "skin" of the device. Depending upon the inherent permeability of the skin to a particular drug, the device may also include means for coadministering
 20 a percutaneous absorption enhancer or an element, such as a membrane interposed between the reservoir and the skin, that regulates the rate at which the drug and/or the enhancer is administered to the skin.

[0003] U.S. Patents 4,379,454 and 4,460,372 describe a device for coadministering a drug and a percutaneous absorption enhancer transdermally. The drug is presented to the skin at a rate in excess of that which the skin is inherently capable of absorbing and the enhancer is presented to the skin at a substantially constant rate that is sufficient
 25 to permit the skin to pass therapeutic levels of drug to circulation. The device includes a membrane interposed between a drug and enhancer-containing reservoir layer and a pressure-sensitive adhesive layer that regulates the rate at which the enhancer is presented to the skin. In the commercial estradiol embodiment of this device (marketed under the mark ESTRADERM) the enhancer is ethanol and the estradiol-ethanol mixture is contained in the reservoir in a fluid form. Using such a form complicates the procedures for manufacturing the device and detracts from the ability to optimize
 30 certain physical characteristics of the device such as thickness, resiliency, and adhesiveness, that are associated with wearability.

[0004] Other patent publications relating to devices for administering estradiol transdermally are German Patent Publications 3 315 245 and 3 315 272, European Patent Publications 0013606 and 0040861 and U.S. Patent 4,438,139.

35 [0005] Patent publications relating to transdermal delivery of opioids in general and fentanyl or fentanyl derivatives or analogs (sufentanil, carfentanil, lofentanil, and alfentanil) are EPA 0171742 and U.S. Patents 4,588,580 and 4,626,539.

[0006] U.S. Patent 4,435,180 describes a transdermal drug-delivery device comprising a body of a mixture of elastomer and drug, the body being in a form such as an arm or wrist band which inherently creates a compressive force when worn to keep the body firmly in contact with the skin.

40 [0007] The focus of much of the prior art relating to transdermal drug delivery has been on the release kinetics of the drug or enhancer from the device.

Disclosure of the Invention

45 [0008] The invention is a transdermal drug delivery device comprising a solid state laminated composite that contains a drug selected from a steroid and fentanyl and its analogs and a percutaneous absorption enhancer, characterized in that said percutaneous absorption enhancer is a fatty acid ester or fatty alcohol ether of a C₂ to C₄ alkanediol where each fatty acid or fatty alcohol portion of the ester or ether is of 8 to 22 carbon atoms.

50 [0009] Another aspect of the invention is the use, as a percutaneous absorption enhancer for a drug selected from a steroid and fentanyl and its analogs of a fatty acid ester or fatty alcohol ether of a C₂ to C₄ alkanediol where each fatty acid or fatty alcohol portion of the ester or ether is of 8 to 22 carbon atoms

Brief Description of the Drawing

55 [0010] Figure 1 shows an enlarged sectional view of one embodiment of the transdermal drug-delivery device of the invention.

[0011] Figures 2 and 3 are graphs of fentanyl flux from the devices described in Examples 16 and 19, respectively, versus time.

Modes for Carrying Out the Invention

[0012] Figure 1 shows a device, generally designated 11, which is an embodiment of the invention and is designed for administering a drug, such as estradiol or fentanyl, transdermally at therapeutically effective rates. Device 11 is in the form of a seven-layer laminated composite that is adapted to be adhered to a predetermined area of unbroken skin. The seven layers of the device are: a first structural layer 12 that forms the upper face surface of the device; a hydrophobic viscoelastic polymer layer 13; a second structural layer 14; a second hydrophobic viscoelastic polymer layer 15; a third structural layer 16; a pressuresensitive adhesive layer 17 which contains the drug; and a release liner layer 18.

[0013] Structural layers 12, 14, and 16 are the components of the composite that provide the composite with resiliency and firmness. In this regard, the term "resiliency" denotes the ability of the composite to recover its size and form following deformation. This ability is a function of the thicknesses of the layers, their yield strengths, and their elastic moduli. The term "firmness" is related to the degree of flexibility of the body and is intended to mean that despite its thinness, the composite does not readily and rapidly fold upon itself during normal handling prior to application to the skin. Resiliency permits the composite to be worn comfortably on areas of the skin, such as joints or other points of flexure, that are normally subjected to mechanical strain with little or no likelihood of the composite disengaging from the skin due to differences in the flexibility or resiliency of the skin and the composite. The firmness of the composite lessens the likelihood that the composite will fold upon itself while being handled prior to application to the skin such that portions of its adhesive surface will contact each other and stick together.

[0014] One or more of the structural layers may contain drug/enhancer, provided same does not impair the structural integrity of the layer(s) or their mechanical properties.

[0015] One or more of the structural layers (12, 14, 16), or hydrophobic viscoelastic polymer layers, or combinations thereof may also be used to impart the device with a desirable or necessary degree of occlusivity which in turn causes the area of skin on which the device is placed to become hydrated. In such a role, layers are selected that have levels of water vapor transmissibility that make the device occlusive to the degree required to cause the area of skin to be hydrated. In such instances it is preferable that the device provide at least about 90% hydration, more preferably at least about 95% hydration of the skin, as measured by a dielectric hydration probe available from Dr. Howard Maibach, U.C.S.F. San Francisco, California. Such occlusivity is desirable when drugs such as estradiol or other steroids are being administered. If the drug being administered is such that skin hydration is not necessary or desirable, it is preferable to use layers that provide a composite that is "breathable", i.e., transmits water vapor from the skin to the atmosphere. Such breathability contributes to the nonocclusive nature of the composite and lessens the likelihood that the area of skin on which the composite is worn will become irritated. In the case of device 11, the hydrophobic viscoelastic polymer layers 13 and 15 are the principal layers that make the device occlusive. Thus, in devices that need not be occlusive, these layers may be eliminated if not needed as reservoir layers, thus providing a five-layer composite, or replaced with water vapor permeable layers. In nonocclusive embodiments of the device the water vapor transmission rate (WVTR) of the laminated composite is typically in the range of 11-18 g/m²-hr (as measured using an Evaporimeter at normal room temperature and humidity, i.e., 20°C, 60% relative humidity).

[0016] The use of a multiplicity of spaced structural laminas has been found to provide better mechanical properties than use of a single structural lamina having a thickness equal to the combined thicknesses of the spaced laminas. Because of this, suitable mechanical properties may be achieved with a thinner composite employing less elastomer.

[0017] Examples of resilient elastomers that may be used to form laminas 12, 14, and 16 are polyether block amide copolymers (e.g., PEBAX copolymers), polyethylene methyl methacrylate block copolymers (EMA) such as NUKRELL polymers, polyurethanes such as PELLATHANE or ESTANE polymers, silicone elastomers, and polyester block copolymers that are composed of hard and soft segments (e.g., HYTREL polymers). The laminas 12, 14, and 16 may be made of the same elastomer or different elastomers. Preferably, they are made of the same resilient elastomer. The structural laminas may be dense (i.e., nonporous) or microporous. The individual thickness of each of these layers will normally be in the range of about 10 to 75 μ m (microns). Laminas 14 and 16 do not constitute rate controlling barriers to diffusion of either drug or, when present, enhancer to the skin (i.e., the rate of drug/enhancer administration does not depend on the rate of diffusion of drug/enhancer through these laminas). Depending upon the particular elastomer, these laminas have varying degrees of water barrier properties.

[0018] Layers 13 and 15 serve: (1) optionally as reservoirs for enhancer and/or drug, (2) as barriers to water vapor transmission, (3) to resist liquid uptake due to the low solubility of water thereon, and (4) to provide additional resiliency and elasticity. In preferred embodiments of an estradiol device, these layers contain enhancer and are composed of a pressure-sensitive adhesive material which is permeable to the enhancer and in which the enhancer is less soluble than in the pressure-sensitive adhesive layer. The incorporation of enhancer into these layers prevents back migration of enhancer from the pressure-sensitive adhesive lamina 17. In such embodiments, layers 13 and 15 will normally contain between about 5% and about 15% by weight enhancer based on the total weight of the layer. The thickness of each of layers 13 and 15 will normally be in the range of 50 to 100 μ m (microns).

[0019] Layers 13 and 15 may be made from the hydrophobic pressure-sensitive adhesive polymers used to make layer 17 (listed below) or other suitable hydrophobic polymers such as styrene-butadiene copolymers. In embodiments in which one or both of these layers serve as drug/enhancer reservoirs, the polymer should be permeable to drug/enhancer. In such instances the polymer will have a diffusion coefficient and exhibit drug/enhancer solubility comparable to those described below with respect to lamina 17.

[0020] Lamina 17 is composed of a pressure-sensitive adhesive optionally containing drug and/or enhancer. When a pressure-sensitive adhesive is used in layers 13 and 15, the same or different material may be used in lamina 17. When lamina 17 functions as a drug/enhancer reservoir, the diffusion coefficient of the adhesive material used in lamina 17 to the drug/enhancer and the solubility of the drug/enhancer in the material are such that the polymer is permeable to the drug/enhancer. Polymers having diffusion coefficients (D) greater than about 10^{-14} cm²/sec, usually in the range of 10^{-8} to 10^{-12} cm²/sec (determined from desorption curves described by Baker, R.W. and Lonsdale, H.K., *Controlled Release: Mechanism and Rates in Advances in Experimental Medicine and Biology*, Vol. 47, Tanquary, A.C. and Lacey, R.E. Eds, Plenum Press, N.Y., 1974), relative to the drug, the enhancer, or the combination thereof, and in which the solubility of the drug/enhancer is greater than about 1 mg/ml, usually in the range of 1 to 50 mg/ml are suitable. Examples of polymer types that have the required drug/enhancer permeability and desirable adhesiveness are polysiloxanes (silicone polymers such as polydimethylsiloxane and polymethylphenylsiloxane), hydrophobic polyacrylates, plasticized ethylenevinylacetate copolymers, low molecular weight polyether block amide copolymers (e.g., PEBAX copolymers), polyurethanes, and rubbery polymers such as polyisobutene. Polysiloxanes and polyisobutenes are preferred.

[0021] The term "drug" as used to describe the principal active ingredient of the device intends a biologically active compound or mixture of compounds that has a therapeutic, prophylactic or other beneficial pharmacological and/or physiological effect on the wearer of the device. Examples of types of drugs that may be used in the invention device are antiinflammatory drugs, analgesics, antiarthritic drugs, antispasmodics, antidepressants, antipsychotic drugs, tranquilizers, antianxiety drugs, narcotic antagonists, antiparkinsonism agents, cholinergic agonists, anticancer drugs, immunosuppression agents, antiviral agents, antibiotic agents, appetite suppressants, antiemetics, anticholinergics, antihistaminics, antimigraine agents, coronary, cerebral or peripheral vasodilators, hormonal agents, contraceptive agents, antithrombotic agents, diuretics, antihypertensive agents, cardiovascular drugs, opioids, and the like. The appropriate drugs of such types are capable of permeating through the skin either inherently or by virtue of treatment of the skin with a percutaneous absorption enhancer. Because the size of the device is limited for patient acceptance reasons, the preferred drugs are those that are effective at low concentration in the blood stream. Examples of specific drugs are steroids such as estradiol, progesterone, demegestone, promegestone, testosterone and their esters, nitrocompounds such as nitroglycerine and isosorbide nitrates, nicotine, chlorpheniramine, terfenadine, triprolidine, hydrocortisone, oxicam derivatives such as piroxicam, ketoprofen, mucopolysaccharidases such as thiomucase, buprenorphine, fentanyl, fentanyl analogs, naloxone, codeine, dihydroergotamine, pizotiline, salbutamol, terbutaline, prostaglandins such as misoprostol and enprostil, omeprazole, imipramine, benzamides such as metoclopramide, scopolamine, peptides such as growth releasing factor and somatostatin, clonidine, dihydropyridines such as nifedipine, verapamil, ephedrine, propranolol, metoprolol, spironolactone, thiazides such as hydrochlorothiazide, flunarizine, sydnone imines such as molsidomine, sulfated polysaccharides such as heparin fractions and the salts of such compounds with pharmaceutically acceptable acids or bases, as the case may be. The drug may be either wholly or partly dissolved in the pressure-sensitive adhesive. The loading of drug in the adhesive will depend on the intended lifetime of the device and will usually be in the range of about 1% to 20% by weight, based on the total weight of the mixture.

[0022] Since the inherent permeability of the skin to some drugs such as estradiol and fentanyl is too low to permit therapeutic levels of such drugs to pass through a reasonably sized area of unbroken skin, it is necessary to coadminister a percutaneous absorption enhancer with such drugs. Accordingly, a percutaneous absorption enhancer is present in layer 17 along with such drug (and optionally in one or more of layer 12, 13, 14, 15, and 16). In addition to affecting the permeability of the skin to the drug, the enhancer may also increase the solubility of drug in the adhesive and thereby increase the permeability of the adhesive to the drug.

[0023] Applicant has found that fatty acid esters (monoester, diester or mixtures thereof) or fatty alcohol ethers (monoether, diether, or mixtures thereof) of C₂ to C₄ alkanediols, where each fatty acid/alcohol portion of the ester/ether is of about 8 to 22 carbon atoms and is straight or branched chain, preferably straight chain, is saturated or has 1 to 3 sites of olefinic unsaturation and has 0 to 2 hydroxyl groups, are phase compatible with the preferred type of hydrophobic polymer, increase the solubility of estradiol in such polymer, and enhance the permeability of skin to estradiol when coadministered to the skin. Esters and ethers of straight chain alkanediols whose hydroxyl groups are on terminal carbon atoms are preferred. Monoesters and diesters of propylene glycol are particularly preferred. Examples of such esters and ethers are ethylene glycol octanoate, ethylene glycol monolaurate, ethylene glycol dilaurate, ethylene glycol monooleate, ethylene glycol monostearate, ethylene glycol dioleate, ethylene glycol monolinoleate, propylene glycol monolaurate, propylene glycol dilaurate, propylene glycol monopalmitate, propylene glycol monostearate, propylene glycol monooleate, butylene glycol monodecanoate, butylene glycol monolaurate, butylene glycol monopalmitate, butylene glycol monostearate, 2-hydroxyethyloctyl ether, 2-hydroxyethyl lauryl ether, 2-hydroxyethylhexadecyl

ether, 2-hydroxyethyleicosyl ether, 3-hydroxypropyl lauryl ether, 3-hydroxypropyl tetradecyl ether, 3-hydroxypropyl octadecyl ether, 4-hydroxybutyl dodecyl ether, and 4-hydroxybutyl octadecyl ether. The enhancer is dispersed in the device in amounts that are sufficient to provide functional amounts of enhancer over the intended lifetime of the device. The loading of enhancer in layer 17 will usually be in the range of 2% to 20% by weight, based on the mixture.

5 **[0024]** It is important to delineate these types of enhancers (i.e., fatty acid esters and others) from solvent-type enhancers (i.e., alcohol, dimethyl sulfoxide, etc.) in that the latter permeate through skin into the circulating blood while the fatty acid ester-type penetrate the skin to interact on that membrane, but do not permeate through the skin (Ritschell, W.A., *Angew. Chem. International Edition* (1969) 8:699). This distinction has also been demonstrated in skin permeation studies using systems manufactured with varying the amount of propylene glycol monolaurate (PGML), as described
10 in the examples. In this regard, the commercial PGML used in the examples was found to contain substantial amounts, i.e., up to 40% by weight) of the dilaurate (PGDL). Commercial PGML may also contain minor amounts (e.g., up to 10% to 15% by weight) of other ingredients, such as methyl laurate or propylene glycol. Thus, as used in the examples the term "PGML" intends such commercial PGML. Using a gas chromatograph method (Hewlett Packard Fast Analysis Capillary, cross-linked dimethyl siloxane 12.5 m x 0.2 mm ID; injector port 200°C, column oven 70-200°C at 20°C/min with initial 2 min hold at 70°C and final 5 min hold at 200°C, detector 200°C, helium carrier gas with a total gas flow rate of 18 ml/min; FID detection; attenuation 2×10^{-12}) with a limit of detection less than 50 ng/ml, no PGML permeation
15 across skin was detected.

[0025] It will be appreciated that other percutaneous absorption enhancers, such as those taught in U.S. Patents 4,379,454 and 4,568,343, may be coadministered with estradiol to enhance the permeability of the skin to estradiol.
20 In this regard, the enhancer should be phase compatible (i.e., it should not bloom) with the components of the layer (s) in which it is incorporated, and its volatility at normal wearing temperatures should be such as to permit it to be made into a solid state device.

[0026] Of course, when the invention device is used to administer drugs other than estradiol or fentanyl to which the permeability of the skin is inherently too low to pass therapeutic amounts, the above described esters or ethers or
25 known enhancers (see, for instance, the above mentioned patents and the references cited in the mentioned patents) will be included in the device and coadministered with the drug. Correlatively, when the device is used to administer a drug to which the permeability of the skin is inherently sufficient to pass therapeutic amounts, it is not necessary to coadminister an enhancer. Thus, in a general terms, the inclusion of an enhancer in the device is optional depending upon the particular drug that is being administered.

30 **[0027]** When layer 17 is the primary reservoir for drug, its thickness will depend upon the intended lifetime of the device. Thicker layers (and hence more drug and, when present, enhancer) will be used to increase the lifetime. In the case of estradiol, the device will typically be designed to have an effective lifetime of about 3 to 14 days; whereas with fentanyl the effective lifetime will be about 1 to 7 days. In estradiol embodiments, the thickness of the reservoir layer will normally be in the range of about 50 to 100 μm (microns), preferably 50 to 75 μm (microns); whereas in fentanyl
35 embodiments it will normally be about 25 to 150 μm (microns) thick.

[0028] Device 11 does not include means for controlling the rate at which either drug or enhancer is administered to the skin. Instead, in the case of an estradiol or fentanyl device employing PGML as enhancer, estradiol/fentanyl is presented to the skin at rates in excess of that which the treated area of the skin is able to absorb, while PGML is presented to the skin in quantities sufficient to allow necessary skin interaction. The system does not control either
40 the rate of administration of estradiol/fentanyl or PGML. Unlike ethanol, increasing the concentrations and thermodynamic activities of the PGML in the system does not increase estradiol/fentanyl flux appreciably beyond a limiting PGML concentration in the range of 6% to 10% in the adhesive layer. At PGML concentrations equal to or above this level, estradiol/fentanyl skin permeation becomes essentially constant and independent of PGML driving force in the system or estradiol loading above the limiting level necessary to provide equilibrium saturation in all layers and components
45 of the composite.

[0029] It should be understood that the concentrations of drug/enhancer in the layers that are specified above are as of the time of manufacture and that these concentrations may change as concentrations reach equilibrium in accordance with solubility parameters.

50 **[0030]** Prior to use, device 11 includes a release liner layer 18. Just prior to use this layer is stripped off the device to expose layer 17. This material will normally be made from a drug/enhancer impermeable material that is inherently strippable or rendered so by techniques such as silicone or fluorocarbon treatment.

[0031] The rate at which drug/enhancer is/are administered from the device to circulation will depend upon the particular drug/enhancer involved and the basal surface area (the area contacting the skin) of the device. In the case of estradiol used to treat postmenopausal symptoms or osteoporosis, the device should provide sufficient supplemental
55 estradiol (in addition to base level in the patient) to yield steady state plasma levels of estradiol in the range of about 20 to 80 pg/ml. In the case of fentanyl used for the relief of post-operative or chronic pain, the device should provide adequate fentanyl to yield steady state plasma levels of fentanyl in the range of about 2 to 10 mg/ml. *In vitro* tests such as that described in Medical Device and Diagnostic Industry (1985) 8:35-42 may be used to estimate the flux of drug

through human cadaver skin from the devices of the invention. The flux of estradiol from device 11 will normally be in the range of 0.05 to 0.4 $\mu\text{g}/\text{cm}^2/\text{hr}$, more usually 0.1 to 0.2 $\mu\text{g}/\text{cm}^2/\text{hr}$. In the case of fentanyl, flux will normally be in the range of 0.2 to 45 $\mu\text{g}/\text{cm}^2/\text{hr}$. The basal surface area of device 11 will usually be in the range of 2.5 to 50 cm^2 .

[0032] Since device 11 has no fluid elements (i.e., it is a solid state device at normal wearing temperatures, i.e., below about 40°C), it is readily manufactured using conventional casting and laminating techniques. Commercially available films may be used for structural layers 12, 14, and 16 and release liner layer 18. Depending upon the composition of the structural layers, the hydrophobic polymer layers may be solution cast directly on them. Alternatively, the hydrophobic polymer layers may be cast onto temporary release liner layers and then laminated to the structural layers. The pressure-sensitive adhesive is blended with drug and enhancer using suitable solvents and blending equipment and cast onto layer 18. The entire assembly may then be laminated together. Lamination may be accomplished by thermal bonding, solvent bonding or through use of adhesives as is known in the art. Devices of desired basal surface area may be punched or otherwise formed from the thus assembled laminated composite.

[0033] The following examples further illustrate the invention. These examples are not intended to limit the invention in any manner. Unless indicated otherwise, proportions referred to in the examples are by weight %.

Example 1

[0034] A drug-pressure-sensitive adhesive mixture containing 5.0% estradiol (E2), 10% propylene glycol monolaurate (PGML, Scher) (commercial PGML from Scher contains about 60% propylene glycol monolaurate, 30% propylene glycol dilaurate and 10% methyl laurate), and 85% polydimethyl siloxane (PDMS, Dow Corning Medical Grade Adhesive 355) was dissolved with trichlorotrifluoroethane (Freon™) to provide a 50%-solids solution. A drug-reservoir pressure-sensitive adhesive layer was prepared by casting the drug-polymer solution onto a fluorocarbon-coated polyester film (3M, 1022) using a 150 μm (micron) gap Gardner knife. The Freon™ was evaporated to yield a 75 μm (micron) thick drug-pressure-sensitive adhesive film. The drug-reservoir pressure-sensitive adhesive film was laminated to an elastic-resilient polyurethane film (25 μm (micron) thick Medifilm 426 Schoeller) to form the drug-reservoir laminate (L1).

[0035] An occlusive-resilient polyisobutene (PIB, L-100 Exxon, LM-MS Exxon, H-1900 Amoco in a weight ratio of 1:3:1) layer was prepared by solvent casting a PIB solution, containing 90% PIB and 10% PGML and dissolved with hexane to provide 32% total solids, with a 500 μm (micron) gap Gardner knife onto a fluorocarbon-coated polyester film (3M, 1022). The hexane was evaporated to yield a 75 μm (micron) thick PIB viscoelastic layer. A 25 μm (micron) thick Medifilm 426 film was laminated to the PIB layer to form the occlusive resilient laminate (L2).

[0036] A 7-layer laminated composite was prepared by first removing the polyester film of the L2 lamina and laminating the exposed PIB layer to the Medifilm 426 surface of an identical L2 lamina (laminating two L2 laminates together). The polyester film of the resultant laminate is then removed and the exposed PIB surface is laminated to the Medifilm 426 surface of the L1 laminate, the polyester film of the L1 laminate serving as the release liner for the 7-layer system.

[0037] The final laminated composite was die cut to fit diffusion cells and E2 steady-state flux across human cadaver skin was determined to be 0.15 to 0.17 $\mu\text{g}/\text{cm}^2/\text{hr}$ for the system at 32°C using the methods described in Medical Device and Diagnostic Industry (1985) 8:35-42. No PGML skin flux could be quantitated using the above-mentioned gas chromatograph method.

[0038] The *in vitro* release of E2 from the 7-layer system was determined, using a reciprocating dissolution apparatus (USP Test Dissolution Method V) at 32°C, to be square-root-time-dependent over 7 days with a total cumulative release of 190 $\mu\text{g}/\text{cm}^2$ in 7 days (the flux was 14.66 $\mu\text{g}/\text{cm}^2/\text{hr}^{1/2}$). The laminated composite was translucent and resilient, allowing the system to stretch with the stretching of skin when worn. The system was worn continuously for 7 days on points of flexure of the skin (such as the wrist) without disengaging from the skin.

Example 2

[0039] An occlusive resilient 7-layer laminated composite was prepared as described in Example 1 using 14% PGML in the L1 laminate instead of 10% PGML. *In vitro* skin flux was determined to be 0.15 $\mu\text{g}/\text{cm}^2/\text{hr}$.

Example 3

[0040] An occlusive resilient 7-layer laminated composite was prepared as described in Example 1 but substituting Medifilm 810 for Medifilm 426 and changing E2 content to 2.0% and 5.5% in L1 and L2 respectively. The adhesive layer in L1 is composed of 10% PGML, 4% silicone oil (Medical Fluid 360, Dow Corning) and 84% PDMS. The adhesive layer of L2 is composed of 10% PGML, 4% silicone oil and 80.5% PDMS instead of 10% PGML and 90% PIB.

[0041] *In vitro* skin flux was determined to be approximately 0.14 $\mu\text{g}/\text{cm}^2/\text{hr}$. During a four day wearing study constant plasma levels were obtained for 20 and 30 cm^2 laminates to be approximately 25 and 32 pg/ml respectively in post-

menopausal female subjects.

Example 4

5 [0042] A 5-layer laminated composite was prepared in a manner similar to that described in Example 1. The polyester layer of L2 was removed and the exposed PIB surface laminated to the Medifilm 426 surface of L1, the polyester layer of L1 serving as the release liner of the final laminate.

[0043] The final laminate was tested for E2 skin flux as described in Example 1 and determined to be $\sim 0.12 \mu\text{g}/\text{cm}^2/\text{hr}$.

10 Example 5

[0044] A 5-layer laminated composite was prepared in a manner similar to Example 2. The polyester layer of L2 was removed and the exposed PIB surface laminated to the Medifilm 426 surface of L1, the polyester layer of L1 serving as the release liner of the final laminate.

15 [0045] The final laminate was tested for E2 skin flux and determined to be $\sim 0.15 \mu\text{g}/\text{cm}^2/\text{hr}$.

[0046] Constant plasma concentration of E2 occurred over a 7 day wearing of 20 and 30 cm^2 laminates. Plasma levels were approximately 30 and 45 pg/ml respectively in postmenopausal female subjects.

Examples 6 and 7

20 [0047] Occlusive resilient 7-layer and 5-layer devices were prepared as in Examples 1 and 4, but substituting Medifilm 810 (polyether amide film, 25 μm (microns) thick) for Medifilm 426. The flux from the 5-layer device was found to be $\sim 0.14 \mu\text{g}/\text{cm}^2/\text{hr}$.

25 Examples 8 and 9

[0048] Occlusive resilient 7-layer and 5-layer devices were prepared as in Examples 6 and 7, but substituting Medifilm 910 (polyethylene methacrylate copolymer, 25 μm (microns) thick) for Medifilm 810. The flux from the 5-layer device was found to be $\sim 0.11 \mu\text{g}/\text{cm}^2/\text{hr}$.

30 Examples 10, 11, and 12

[0049] Occlusive resilient laminated composites are prepared as described in Example 1, but substituting progesterone, demegestone, or promegestone for E2 in the drug-reservoir pressure-sensitive adhesive.

35 Example 13, 14, and 15

[0050] Occlusive resilient laminated composites are prepared as described in Example 1 containing 2.5% E2 and 2.5% of either progesterone, demegestone, or promegestone in the drug-reservoir pressure-sensitive adhesive.

40 Example 16

45 [0051] A drug-polymer reservoir containing 3.5% fentanyl base and 96.5% PIB was dissolved in n-hexane to provide 33% solids solution. A drug reservoir lamina was prepared by casting the drug-polymer reservoir solution onto a fluorocarbon-coated polyester film (3M, 1022) using a 190 μm (micron) casting blade. The hexane was evaporated to yield a 63 μm (micron) thick drug reservoir film. The drug reservoir film was then laminated onto a structural film consisting of 12.5 μm (micron) thick polyester film (3M, 1220) such that the polyester film would serve as a release strip to provide the outer backing-structural lamina/drug reservoir lamina composite (L1).

50 [0052] A pressure-sensitive adhesive consisting of 1 5% fentanyl base, 3.5% PGML (Scher) 2.5% silicone oil (100 centistokes, Dow Corning Medical Fluid) and 92 5% amine resistant polydimethylsiloxane (Dow Corning X7-2900) was dissolved with trichlorotrifluoroethane (FreonTM) to provide a 50% solution. The adhesive was cast using a 150 μm (micron) gap Gardner wet film applicator onto a fluorocarbon-coated polyester film (3M, 1022) and the solvent was evaporated to provide a 75 μm (micron) thick contact adhesive layer. The adhesive was laminated onto a second moisture vapor permeable structural support film consisting of 12.5 μm (micron) thick Medifilm 428 or 827 such that the polyester film would act as a release strip to provide a structural support/adhesive/release strip laminate composite (L2).

55 [0053] The fluorocarbon-coated polyester release strip of L1 was removed and the drug-reservoir surface of L1 was laminated to the Medifilm 428 or 827 surface of L2 to provide the final laminated composite with the polyester film of

L2 serving as a peelable release strip for the final laminate. The laminate was allowed to equilibrate for a week prior to skin flux evaluation.

[0054] The laminate was die cut to fit diffusion cells and fentanyl base steady state flux through cadaver skin was determined at 32°C to be 9.7 $\mu\text{g}/\text{cm}^2/\text{hr}$. Fentanyl flux as a function of time is depicted in Figure 2. Perfect sink condition was maintained by using phosphate buffer (pH=6.0) as a receiver fluid. The cumulative amount of fentanyl base released by *in vitro* dissolution at 25°C was square root time dependent over 48 hours (correlation coefficient = 0.99, slope 79.4 $\text{g}/\text{cm}^2/\text{h}^{\frac{1}{2}}$), suggesting that diffusion of fentanyl base was under membrane (skin) control.

Example 17

[0055] A laminated composite was prepared as described in Example 16 except that no structural layer, i.e., Medifilm 827 or 428, was included. Steady-state skin flux of 17.5 $\mu\text{g}/\text{cm}^2/\text{hr}$ was obtained with this device. The fentanyl skin flux was increased two-fold by removal of the Medifilm layer from the laminated composite. This may be due to uptake of PGML as well as fentanyl free base by the Medifilm layer.

Example 18

[0056] A monolithic device was prepared which consisted of 3.2% fentanyl base, 1.2, 2.5 or 5% of PGML, 2.5% silicone oil and 89.3 to 93.1% of amine resistant polydimethylsiloxane which also acts as an adhesive. Fentanyl concentration was above saturation (i.e., unit thermodynamic activity) in the 1.2 and 2.5% PGML formulations, while in the 5% PGML formulation fentanyl concentration is nearly at saturation. Skin permeation studies were done as described in Example 16. The effect of PGML concentration on the flux of fentanyl through cadaver skin is summarized in the table below.

%PGML	Fentanyl Skin Flux ($\mu\text{g}/\text{cm}^2/\text{hr}$)	T_{lag} (hr)
5.0	28.0	0.58
2.5	45.5	0.51
1.2	22.9	0.38

[0057] As shown, fentanyl flux increases as the concentration of PGML increases from 1.2 to 2.5%, however, flux decreases as the PGML concentration increases to 5%. It appears that at low PGML concentrations the fentanyl skin flux is under solvent control (diffusion layer control) where the flux from saturated solutions increases with increasing concentration of PGML. As the fraction of PGML increased, the flux is under membrane control, causing a decrease in fentanyl flux.

Example 19

[0058] A monolithic device similar to that of Example 18 was prepared using PIB, 0 to 8.6% PGML and 3.5% fentanyl base. Skin permeation studies were done as described in Example 16. Fentanyl skin fluxes from different formulations are depicted in Figure 3. The effect of PGML concentration on the flux of fentanyl through cadaver skin is summarized in the table below.

%PGML	Fentanyl base (%)	Fentanyl Skin Flux ($\mu\text{g}/\text{cm}^2/\text{hr}$)	T_{lag} (hr)
0	2.5	8.71	0.67
2.0	2.5	11.9	0.18
8.6	2.5	11.8	<0.1
5.0	5.0	15.2	>0.1

[0059] It is apparent from these data that fentanyl flux increases 27% (11.9-8.71/8.71) when 2% PGML is incorporated in the PIB. Nevertheless, the fentanyl flux from the PIB formulation was considerably lower than that of amine resistant polydimethylsiloxane (Example 18). This may be due to lower thermodynamic activity of fentanyl in PIB than in amine resistant polydimethylsiloxane, since fentanyl has a higher solubility in PIB owing to its higher lipophilicity.

Examples 20 and 21

[0060] Three layer composites were prepared with a drug reservoir lamina consisting of 2.5% fentanyl base, 1.5%

PGML and 96% acrylate polymer and a pressure-sensitive adhesive consisting of 1.5% fentanyl base, 1.5% PGML, 2.5% silicone oil (100 centistokes) and 94.5% amine resistant polydimethylsiloxane. Acrylate polymer consists of 1 part of Gelva 737 acrylate copolymer and 2 parts of Gelva 788 acrylate polymer (Monsanto). The devices were made either occlusive using fluoro-carbon-coated polyester film (3M, 1220) as a backing or nonocclusive using 25 μm (micron) thick polyether block amide copolymer (Medifilm 827). The nonocclusive device allowed water vapour to be freely transported from the area of the skin on which it was worn to the atmosphere.

[0061] Fentanyl skin flux from occlusive system was 2.96 $\mu\text{g}/\text{cm}^2/\text{hr}$, whereas the nonocclusive system gave a flux of 0.37 $\mu\text{g}/\text{cm}^2/\text{hr}$. The lower flux of fentanyl from the nonocclusive system is due to the dehydration of skin. Although the fentanyl flux decreased significantly from the nonocclusive system, a steady-state flux of 0.37 $\mu\text{g}/\text{cm}^2/\text{hr}$ was maintained up to 72 hours.

[0062] Modifications of the above-described modes for carrying out the invention that are obvious to those of ordinary skill in the field of transdermal drug-delivery devices and related fields are intended to be within the scope of the following claims.

Claims

1. A transdermal drug delivery device comprising a solid state laminated composite that contains a drug selected from a steroid and fentanyl and its analogs and a percutaneous absorption enhancer, characterized in that said percutaneous absorption enhancer is a fatty acid ester or fatty alcohol ether of a C_2 to C_4 alkanediol where each fatty acid or fatty alcohol portion of the ester or ether is of 8 to 22 carbon atoms.
2. The transdermal drug delivery device of claim 1 wherein the drug is a steroid.
3. The transdermal drug delivery device of claim 1 wherein the drug is estradiol.
4. The transdermal drug delivery device of claim 1 wherein the drug is fentanyl or a fentanyl analog.
5. The transdermal drug delivery device of any one of claims 1 to 4 wherein the alkanediol is propylene glycol.
6. The transdermal drug delivery device of claim 5 wherein the fatty acid ester of propylene glycol is a monoester, diester or mixtures thereof.
7. The transdermal drug delivery device of claim 5 or claim 6 wherein each fatty acid portion contains 12 carbon atoms.
8. Use, as a percutaneous absorption enhancer for a drug selected from a steroid and fentanyl and its analogs, of a fatty acid ester or fatty alcohol ether of a C_2 to C_4 alkanediol, where each fatty acid or fatty alcohol portion of the ester or ether is of 8 to 22 carbon atoms.
9. Use as claimed in claim 8 wherein the drug is a steroid.
10. Use as claimed in claim 8 wherein the drug is estradiol.
11. Use as claimed in claim 8 wherein the drug is fentanyl or a fentanyl analog.
12. Use as claimed in any one of claims 8 to 11 wherein the alkanediol is propylene glycol.
13. Use as claimed in claim 12 wherein the fatty acid ester of propylene glycol is a monoester, diester or mixtures thereof.
14. Use as claimed in claim 12 or claim 13 wherein each fatty acid portion contains 12 carbon atoms.

Patentansprüche

1. Vorrichtung zur transdermalen Wirkstoffabgabe, welche einen festen laminierten Verbundkörper umfaßt, der einen Wirkstoff enthält, der ausgewählt ist aus einem Steroid und Fentanyl und seinen Analoga, und einen perkutanen Absorptionsförderer, dadurch gekennzeichnet, daß der perkutane Absorptionsverstärker ein Fettsäureester oder

Fettalkoholether eines C₂- bis C₄-Alkandiolis ist, wobei jeder Fettsäure- oder Fettalkoholteil des Esters oder Ethers 8 bis 22 Kohlenstoffatome aufweist.

2. Vorrichtung zur transdermalen Wirkstoffabgabe nach Anspruch 1, dadurch gekennzeichnet, daß der Wirkstoff ein Steroid ist.
3. Vorrichtung zur transdermalen Wirkstoffabgabe nach Anspruch 1, dadurch gekennzeichnet, daß der Wirkstoff Estradiol ist.
4. Vorrichtung zur transdermalen Wirkstoffabgabe nach Anspruch 1, dadurch gekennzeichnet, daß der Wirkstoff Fentanyl oder ein Fentanyl-Analog ist.
5. Vorrichtung zur transdermalen Wirkstoffabgabe nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, daß das Alkandiol Propylenglykol ist.
6. Vorrichtung zur transdermalen Wirkstoffabgabe nach Anspruch 5, dadurch gekennzeichnet, daß der Fettsäureester von Propylenglykol ein Monoester, Diester oder Mischungen derselben ist.
7. Vorrichtung zur transdermalen Wirkstoffabgabe nach Anspruch 5 oder Anspruch 6, dadurch gekennzeichnet, daß jeder Fettsäureteil 12 Kohlenstoffatome enthält.
8. Verwendung eines Fettsäureesters oder Fettalkoholethers eines C₂- bis C₄-Alkandiolis als ein perkutaner Absorptionsförderer für einen Wirkstoff, der ausgewählt ist aus einem Steroid und Fentanyl und seinen Analoga, wobei jeder Fettsäure- oder Fettalkoholteil des Esters oder Ethers 8 bis 22 Kohlenstoffatome aufweist.
9. Verwendung nach Anspruch 8, dadurch gekennzeichnet, daß der Wirkstoff ein Steroid ist.
10. Verwendung nach Anspruch 8, dadurch gekennzeichnet, daß der Wirkstoff Estradiol ist.
11. Verwendung nach Anspruch 8, dadurch gekennzeichnet, daß der Wirkstoff Fentanyl oder ein Fentanyl-Analog ist.
12. Verwendung nach einem der Ansprüche 8 bis 11, dadurch gekennzeichnet, daß das Alkandiol Propylenglykol ist.
13. Verwendung nach Anspruch 12, dadurch gekennzeichnet, daß der Fettsäureester von Propylenglykol ein Monoester, Diester oder Mischungen derselben ist.
14. Verwendung nach Anspruch 12 oder Anspruch 13, dadurch gekennzeichnet, daß jeder Fettsäureteil 12 Kohlenstoffatome enthält.

Revendications

1. Dispositif de distribution d'un médicament transdermique comprenant un composite stratifié à l'état solide qui contient un médicament choisi parmi un stéroïde et le fentanyl et ses analogues et un agent de renforcement d'absorption percutanée, caractérisé en ce que ledit agent de renforcement d'absorption percutanée est un ester d'acide gras ou un éther d'alcool gras d'un alcanediol en C2-4, chaque portion d'acide gras ou d'alcool gras de l'ester ou de l'éther ayant 8 à 22 atomes de carbone.
2. Dispositif de distribution d'un médicament transdermique selon la revendication 1, dans lequel le médicament est un stéroïde.
3. Dispositif de distribution d'un médicament transdermique selon la revendication 1, dans lequel le médicament est un oestradiol.
4. Dispositif de distribution d'un médicament transdermique selon la revendication 1, dans lequel le médicament est le fentanyl ou un analogue du fentanyl.
5. Dispositif de distribution d'un médicament transdermique selon les revendications 1 à 4, dans lequel l'alcanediol

est le propylène-glycol.

6. Dispositif de distribution d'un médicament transdermique selon la revendication 5, dans lequel l'ester d'acide gras de propylène-glycol est un monoester, diester ou leurs mélanges.
7. Dispositif de distribution d'un médicament transdermique selon la revendication 5 ou 6, dans lequel chaque portion d'acide gras contient 12 atomes de carbone.
8. Utilisation, à titre d'agent de renforcement d'absorption percutanée pour un médicament choisi parmi un stéroïde et le fentanyl et ses analogues, d'un ester d'acide gras ou d'un éther d'alcool gras d'un alcanediol en C2-4, chaque portion d'acide gras ou d'alcool gras de l'ester ou de l'éther étant de 8 à 22 atomes de carbone.
9. Utilisation selon la revendication 8, dans laquelle le médicament est un stéroïde.
10. Utilisation selon la revendication 9, dans laquelle le médicament est un oestradiol.
11. Utilisation selon la revendication 8, dans laquelle le médicament est le fentanyl ou un analogue du fentanyl.
12. Utilisation selon l'une quelconque des revendications 8 à 11, dans laquelle l'alcanediol est le propylène-glycol.
13. Utilisation selon la revendication 12 dans laquelle l'ester d'acide gras de propylène-glycol est un monoester, diester ou leurs mélanges.
14. Utilisation selon la revendication 12 ou 13, dans laquelle chaque portion d'acide gras contient 12 atomes de carbone.

Figure 1




Figure 2




Figure 3
Fentanyl (3.5% Loading) Skin Flux from Monolith PIB (1:3:1) with or without PGML

